Hippocampal volume changes after (R,S)-ketamine administration in patients with major depressive disorder and healthy volunteers.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Depressive Disorder, Major*/diagnostic imaging ; Depressive Disorder, Major*/drug therapy ; Depressive Disorder, Major*/pathology ; Depressive Disorder, Treatment-Resistant* ; Ketamine*/pharmacology ; Ketamine*/therapeutic use; Humans ; Healthy Volunteers ; Hippocampus/pathology ; Treatment Outcome ; Randomized Controlled Trials as Topic

The hippocampus and amygdala have been implicated in the pathophysiology and treatment of major depressive disorder (MDD). Preclinical models suggest that stress-related changes in these regions can be reversed by antidepressants, including ketamine. Clinical studies have identified reduced volumes in MDD that are thought to be potentiated by early life stress and worsened by repeated depressive episodes. This study used 3T and 7T structural magnetic resonance imaging data to examine longitudinal changes in hippocampal and amygdalar subfield volumes associated with ketamine treatment. Data were drawn from a previous double-blind, placebo-controlled, crossover trial of healthy volunteers (HVs) unmedicated individuals with treatment-resistant depression (TRD) (3T: 18 HV, 26 TRD, 7T: 17 HV, 30 TRD) who were scanned at baseline and twice following either a 40 min IV ketamine (0.5 mg/kg) or saline infusion (acute: 1-2 days, interim: 9-10 days post infusion). No baseline differences were noted between the two groups. At 10 days post-infusion, a slight increase was observed between ketamine and placebo scans in whole left amygdalar volume in individuals with TRD. No other differences were found between individuals with TRD and HVs at either field strength. These findings shed light on the timing of ketamine's effects on cortical structures.
(© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.)

Biol Psychiatry. 2006 Jun 15;59(12):1136-43. (PMID: 16797263)
Biol Psychiatry. 2016 Feb 15;79(4):282-92. (PMID: 25842202)
Int J Neuropsychopharmacol. 2019 Aug 1;22(8):513-522. (PMID: 31175352)
Am J Psychiatry. 2003 Aug;160(8):1516-8. (PMID: 12900317)
Biol Psychiatry. 1999 Nov 1;46(9):1181-91. (PMID: 10560024)
Transl Psychiatry. 2020 Aug 3;10(1):264. (PMID: 32747631)
Int J Neurosci. 2008 Nov;118(11):1582-93. (PMID: 18853335)
J Neurosci. 2000 Dec 15;20(24):9104-10. (PMID: 11124987)
Curr Neurovasc Res. 2015;12(1):73-84. (PMID: 25613382)
Neuroimage. 2015 Jul 15;115:117-37. (PMID: 25936807)
J Psychiatry Neurosci. 2009 Jan;34(1):41-54. (PMID: 19125212)
Neuroimage. 2017 Jul 15;155:370-382. (PMID: 28479476)
Transl Psychiatry. 2021 Apr 1;11(1):200. (PMID: 33795646)
Neuroimage. 2012 Jul 16;61(4):1402-18. (PMID: 22430496)
Neuropsychopharmacology. 2017 Jul;42(8):1739-1746. (PMID: 28272497)
Neuroimage Clin. 2022;36:103157. (PMID: 36027717)
J Behav Ther Exp Psychiatry. 2000 Jun;31(2):73-86. (PMID: 11132119)
Am J Psychiatry. 2020 May 1;177(5):381-390. (PMID: 32354265)
Chronic Stress (Thousand Oaks). 2020 Sep 22;4:2470547020944553. (PMID: 33015518)
Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3908-13. (PMID: 8632988)
Br J Psychiatry. 1979 Apr;134:382-9. (PMID: 444788)
Int J Neuropsychopharmacol. 2015 Mar 30;18(8):. (PMID: 25829180)
Mol Psychiatry. 2017 Sep;22(9):1352-1358. (PMID: 28115740)
Science. 2019 Apr 12;364(6436):. (PMID: 30975859)
Brain Connect. 2013;3(5):523-35. (PMID: 23980912)
Biol Psychiatry. 2015 Feb 1;77(3):210-211. (PMID: 25542516)
J Magn Reson Imaging. 2017 Nov;46(5):1456-1463. (PMID: 28225578)
Neuroimage. 2010 Dec;53(4):1244-55. (PMID: 20600995)
Mol Psychiatry. 2008 Nov;13(11):993-1000. (PMID: 18504424)
Science. 2010 Aug 20;329(5994):959-64. (PMID: 20724638)
Biol Psychiatry. 2013 Jul 1;74(1):62-8. (PMID: 23419546)
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Apr 20;91:28-37. (PMID: 30099082)
Biol Psychiatry. 2019 Mar 15;85(6):487-497. (PMID: 30528746)
Hum Brain Mapp. 2016 May;37(5):1941-52. (PMID: 26915535)
Expert Rev Clin Pharmacol. 2021 Oct;14(10):1317-1319. (PMID: 34227438)
Mol Psychiatry. 2016 Jun;21(6):806-12. (PMID: 26122586)
PLoS One. 2014 Dec 16;9(12):e115551. (PMID: 25514672)
Biol Psychiatry. 2021 Jun 1;89(11):1096-1105. (PMID: 33637303)
Am J Psychiatry. 2004 Apr;161(4):598-607. (PMID: 15056502)
J Psychopharmacol. 2015 May;29(5):591-5. (PMID: 25122038)
Trends Psychiatry Psychother. 2018 Oct-Dec;40(4):369-378. (PMID: 30234890)
Neuroimage. 2017 Feb 1;146:132-147. (PMID: 27864083)
Front Neurosci. 2022 Mar 25;16:796129. (PMID: 35401097)
Hum Brain Mapp. 2018 Apr;39(4):1743-1754. (PMID: 29341323)
J Affect Disord. 2012 Dec 20;143(1-3):253-6. (PMID: 22840623)
Hum Brain Mapp. 2016 Mar;37(3):1080-90. (PMID: 26821769)
Neuroimage. 2015 May 1;111:526-41. (PMID: 25596463)
Neuroimage. 2020 Sep;218:116932. (PMID: 32416226)
Neuroimage. 2011 Jul 1;57(1):19-21. (PMID: 21376812)
Ann Neurosci. 2021 Jan;28(1-2):82-93. (PMID: 34733059)
Am J Psychiatry. 2004 Nov;161(11):1957-66. (PMID: 15514393)
Biochem Med (Zagreb). 2015 Jun 05;25(2):141-51. (PMID: 26110027)
Biol Psychiatry. 2004 Aug 1;56(3):140-5. (PMID: 15271581)
Transl Psychiatry. 2020 Feb 25;10(1):78. (PMID: 32098947)
Neuroimage. 2020 Apr 15;210:116563. (PMID: 31972281)
Mol Psychiatry. 2019 Jul;24(7):1040-1052. (PMID: 29487402)
Neuroimage. 2012 Aug 15;62(2):774-81. (PMID: 22248573)
Mol Psychiatry. 2011 Mar;16(3):252-64. (PMID: 20661246)
Nat Commun. 2015 Jul 07;6:7582. (PMID: 26151911)
Neuroimage. 2016 Nov 1;141:542-555. (PMID: 27426838)
Sci Rep. 2019 Jul 15;9(1):10166. (PMID: 31308432)

ZIA MH002857 United States ImNIH Intramural NIH HHS; ZIAMH002857 United States NH NIH HHS

690G0D6V8H (Ketamine)

Date Created: 20240224 Date Completed: 20240226 Latest Revision: 20240307

20250114

PMC10894199

10.1038/s41598-024-54370-9

38402253